Anti-RSV Recombinant Antibody Products

Loading...

Anti-RSV Products

Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

For Research Use Only. Not For Clinical Use.

Respiratory syncytial virus (RSV), a pathogen of substantial global health concern, remains a focal point in virological research. Creative Biolabs has developed a comprehensive suite of highly specific anti-RSV recombinant antibodies using advanced molecular engineering platforms. These reagents enable systematic investigation of viral entry mechanisms and antigenic profiles, supporting the rational design of targeted therapeutic strategies.

RSV: A Significant Target for Antiviral Therapy

Driven by its major cause of severe lower respiratory tract illness in vulnerable groups like newborns, young children, and older people, Respiratory Syncytial Virus (RSV) remains a priority pathogen in biomedical research. Years of challenges in vaccine and antiviral research have now turned into clinical success, shown by the approval of new vaccinations and monoclonal antibody treatments. Modern research mostly focuses on clarifying the etiology of RSV, determining structural factors such as the fusion (F) and attachment (G) glycoproteins for therapeutic targeting, and developing age-stratified immunization programs. These initiatives seek to reduce the great worldwide health load caused by RSV-associated illness and death.

Alternative Names

Respiratory syncytial virus; human respiratory syncytial virus; human orthopneumovirus; hRSV.

Background

Human orthopneumovirus, formerly Human respiratory syncytial virus (HRSV), is a syncytial virus that causes respiratory tract infections. It is a major cause of lower respiratory tract infections and hospital visits during infancy and childhood. A prophylactic medication, palivizumab, can be employed to prevent HRSV in preterm (under 35 weeks gestation) infants, infants with certain congenital heart defects (CHD) or bronchopulmonary dysplasia (BPD), and infants with congenital malformations of the airway.

Anti-RSV rAb Products

Designed for optimal target binding and precision, Creative Biolabs offers a comprehensive selection of anti-RSV recombinant antibodies featuring versatile molecular designs that cater to various applications, such as immune profiling, oncogenic pathway analysis, and therapeutic screening. Our rigorous bioprocessing and thorough analytical validation, which includes structural epitope mapping and ligand interaction studies, ensure consistent batch quality. This integration of cutting-edge protein engineering with streamlined manufacturing produces biologics that demonstrate enhanced binding and selective discrimination, essential for both mechanistic studies and the development of innovative therapeutics.

Table 1. Featured anti-RSV recombinant antibody products at Creative Biolabs.

Creative Quality Control

Creative Biolabs offers anti-RSV recombinant antibodies that are meticulously engineered for superior antigen selectivity and binding kinetics, backed by a comprehensive multiphase quality assurance system. These antibodies exhibit extraordinary performance, verified for consistency across batches using multimodal analytics and validated by extensive functional characterisation throughout a range of tests.

Customer Reviews

Excellent

Ku***y
Recombinant Human Anti-RSV Antibody (AM14) (PABL-321)

In our neutralization studies, Creative Biolabs' anti-RSV protein antibody has shown rather remarkable results. Consistent and dependable findings came from the in vitro studies showing the antibody clearly stopped viral entrance. Given the little off-target effects in our cell culture studies, we value the great specificity. Evaluation of our novel RSV-targeted antivirals depends on this antibody.

3/Oct/2023

Excellent

Li***y
Recombinant Human Anti-RSV Antibody (D25) (PABL-322)

We employed Creative Biolabs' anti-RSV antibody as a positive control for passive immunization in our in vivo investigations assessing the protective effectiveness of possible vaccine candidates against RSV challenge. In our animal model, the antibody showed significant protection that matched published findings. Though the in vivo uses required careful evaluation of dose and delivery methods, the constant protective effect found strengthened the validity of our study strategy. Designing our research also benefited much from the comprehensive characterization data supplied by Creative Biolabs.

27/Mar/2024

Excellent

Ma***y
Human Anti-RSV Recombinant Antibody (clone B21m) (PABL-693)

For our flow cytometry panels to find RSV-infected cells in respiratory samples, we used Creative Biolabs' anti-RSV antibody targeting the G protein. Bright and vivid staining made it possible to clearly distinguish infected from uninfected cells. Although we did have to maximize the antibody concentration for our particular method, the obtained results were rather useful for estimating viral load and comprehending infection dynamics. One major benefit for our diagnostic study has been the antibody's constant performance throughout many sample types.

10/Feb/2025

rAb Production

Creative Biolabs provides researchers all over a regular and reliable source of premium anti-RSV recombinant antibodies. Our carefully crafted and confirmed antibodies guarantee outstanding quality and performance across many research uses by use of modern recombinant technology. Our goal is to hasten scientific progress by arming researchers with consistent reagents required to untangle the complexity of RSV signaling in different biological settings.

Featured Anti-RSV Recombinant Antibody Production Platforms
Fig.7 Milligram-scale anti-RSV recombinant antibody production.

Fig.8 Gram-scale anti-RSV recombinant antibody production.

rAb Modalities

Creative Biolabs provides high-quality, customized anti-RSV recombinant antibodies for research. These antibodies are carefully engineered to satisfy the demands of local, national, and worldwide research groups in various formats.

Fig.9 Full-length anti-RSV recombinant antibody production and modalities.

RSV-Targeted Drug Information

Table 2. Public drug targeting RSV.

(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)

As a prominent entity in antibody development, Creative Biolabs combines deep expertise and experience in RSV research and antibody engineering to provide a range of effective tools for RSV research and the development of RSV-targeted therapeutics. If you would like to learn more about our anti-RSV recombinant antibodies, please feel free to get in touch with us.